Immunovia AB ( (IMMVF) ) has released its Q3 earnings. Here is a breakdown of the information Immunovia AB presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immunovia AB is a company specializing in the early detection of pancreatic cancer, operating within the healthcare diagnostics industry. The company is known for its innovative approach to cancer diagnostics, particularly with its recent launch of the PancreaSure test.
In its latest earnings report for the third quarter of 2025, Immunovia highlighted the successful commercial launch of its PancreaSure test, which is designed for early detection of pancreatic cancer. The company reported net sales of 101 KSEK, primarily from royalties, and an operating loss of 25.5 MSEK, which is an improvement from the previous year’s loss.
Key financial metrics include a reduction in cash burn rate to 5.4 MSEK per month, below the expected 8 to 10 MSEK, and a secured bridge loan of 19 MSEK. The PancreaSure test has garnered significant interest from key opinion leaders and has been validated by the scientific community, receiving accolades such as the ‘Distinguished Abstract Award’. Additionally, Immunovia has made strides towards Medicare reimbursement with a preliminary payment determination of $897 for the PancreaSure test.
Looking ahead, Immunovia aims to expand its commercial reach by recruiting strategic account managers to increase the adoption of PancreaSure among high-risk surveillance centers. The company is also focused on securing reimbursement from both government and commercial insurance providers, which is crucial for its future growth. With the recent successful rights issue, Immunovia is well-positioned financially to support its commercial and research endeavors into 2026.